Novartis AG $NVS Stock: Fisher Asset Management LLC Grows Stake

Fisher Asset Management LLC grew its stake in Novartis AG (NYSE:NVS) by 8.0% during the third quarter, HoldingsChannel reports. The fund owned 16,762,528 shares of the company’s stock after acquiring an additional 1,239,150 shares during the quarter. Fisher Asset Management LLC’s holdings in Novartis were worth $2,389,834,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Bank of America Corp DE grew its position in shares of Novartis by 9.1% in the 1st quarter. Bank of America Corp DE now owns 4,962,794 shares of the company’s stock worth $758,067,000 after buying an additional 413,778 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Novartis by 0.8% during the second quarter. Envestnet Asset Management Inc. now owns 2,330,979 shares of the company’s stock worth $365,308,000 after purchasing an additional 19,595 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Novartis by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 2,275,938 shares of the company’s stock valued at $347,649,000 after purchasing an additional 41,520 shares during the last quarter. WCM Investment Management LLC purchased a new stake in shares of Novartis during the 1st quarter valued at $220,004,000. Finally, Sei Investments Co. boosted its position in shares of Novartis by 9.6% in the 1st quarter. Sei Investments Co. now owns 619,274 shares of the company’s stock worth $94,594,000 after purchasing an additional 54,262 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

More Novartis News

Here’s some of the latest news about NVS:

• Positive Sentiment: Zacks Research raised its FY2026 EPS estimate to $9.06 from $8.83 and its FY2027 estimate to $9.91 from $9.75. It also increased several quarterly forecasts, including Q3 2027 to $2.57 from $2.45. The revisions suggest improved expectations for some periods, though the FY2026 estimate is close to the cited $9.08 consensus. Zacks Research estimate revisions
• Neutral Sentiment: Novartis presented long-term ianalumab data for Sjögren’s disease. The update may draw attention to its drug pipeline, but the article information provided does not describe the results or indicate a change to the drug’s commercial outlook. Long-term ianalumab data article
• Negative Sentiment: Zacks Research trimmed its FY2028 EPS forecast to $10.62 from $10.69 and lowered estimates for some quarters, including Q1 2028 to $2.45 from $2.54. These cuts temper the positive revisions, though they are modest and concern future periods. Zacks Research estimate revisions

Novartis Stock Performance

NVS opened at $160.16 on Friday. The firm has a fifty day moving average price of $149.18 and a 200 day moving average price of $152.56. The stock has a market cap of $305.61 billion, a P/E ratio of 18.03, a P/E/G ratio of 2.93 and a beta of 0.40. Novartis AG has a 1 year low of $123.24 and a 1 year high of $170.46. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.88 and a quick ratio of 0.70.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.25 by $0.21. The firm had revenue of $15.03 billion for the quarter, compared to analyst estimates of $14.53 billion. Novartis had a net margin of 18.11% and a return on equity of 41.04%. Novartis’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period last year, the company posted $2.25 EPS. Equities research analysts anticipate that Novartis AG will post 9.10 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Sanford C. Bernstein reaffirmed a “neutral” rating on shares of Novartis in a research report on Wednesday, July 22nd. DZ Bank started coverage on Novartis in a research note on Wednesday, October 28th. They issued a “hold” rating for the company. Royal Bank Of Canada restated a “sector perform” rating on shares of Novartis in a research note on Wednesday, October 28th. JPMorgan Chase & Co. restated a “buy” rating on shares of Novartis in a report on Sunday, August 9th. Finally, Weiss Ratings lowered shares of Novartis from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, November 4th. Six research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $152.25.

Novartis Profile

Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.